We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
+11.45%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$76M
AUM Growth
-$11.1M
(-13%)
Cap. Flow
+$112M
Cap. Flow
% of AUM
147.28%
Top 10 Holdings %
Top 10 Hldgs %
38.02%
Holding
408
New
159
Increased
53
Reduced
54
Closed
131
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$3.17M |
| 2 |
K
Kellanova
K
|
+$2.19M |
| 3 |
FL
Foot Locker
FL
|
+$2.04M |
| 4 |
General Mills
GIS
|
+$1.95M |
| 5 |
lululemon athletica
LULU
|
+$1.74M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$9.7M |
| 2 |
JPMorgan Chase
JPM
|
+$3.58M |
| 3 |
Gilead Sciences
GILD
|
+$3.38M |
| 4 |
Constellation Brands
STZ
|
+$2.74M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.66% |
| 2 | Consumer Staples | 16.16% |
| 3 | Consumer Discretionary | 9.31% |
| 4 | Communication Services | 3.38% |
| 5 | Materials | 2.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Abbott
ABT
$175B
| $7.15M | 9.41% |
160,970
+13,000
| +9% | +$562K |
|
|
2
General Mills
GIS
$20.3B
| $5.1M | 6.71% |
86,397
+31,920
| +59% | +$1.95M |
|
|
GWPH
3
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $3.12M | 4.11% |
+25,829
| New | +$3.17M |
|
4
Akebia Therapeutics
AKBA
$359M
| $2.64M | 3.47% |
286,477
-52,163
| -15% | -$509K |
|
|
K
5
DELISTED
Kellanova
K
| $2.54M | 3.35% |
37,301
+31,793
| +577% | +$2.19M |
|
|
FL
6
DELISTED
Foot Locker
FL
| $2.12M | 2.79% |
+28,300
| New | +$2.04M |
|
7
Mondelez International
MDLZ
$78.3B
| $1.76M | 2.32% |
40,904
+27,170
| +198% | +$1.2M |
|
|
POT
8
DELISTED
Potash Corp Of Saskatchewan
POT
| $1.71M | 2.25% |
100,080
+5,000
| +5% | +$90.6K |
|
|
9
lululemon athletica
LULU
$13.2B
| $1.38M | 1.81% |
+26,500
| New | +$1.74M |
|
|
SAGE
10
DELISTED
Sage Therapeutics
SAGE
| $1.36M | 1.8% |
19,213
+3,235
| +20% | +$189K |
|
11
United Therapeutics
UTHR
$22.7B
| $1.32M | 1.73% |
9,723
+4,850
| +100% | +$735K |
|
|
KITE
12
CALL
DELISTED
Kite Pharma, Inc.
KITE
| $1.29M | 1.69% |
81,700
+61,700
| +309% | +$3.82M |
|
|
COL
13
DELISTED
Rockwell Collins
COL
| $1.26M | 1.66% |
+13,000
| New | +$1.22M |
|
|
TWX
14
DELISTED
Time Warner Inc
TWX
| $1.21M | 1.59% |
12,385
-5,001
| -29% | -$484K |
|
|
MDCO
15
DELISTED
Medicines Co
MDCO
| $1.18M | 1.55% |
+24,099
| New | +$1.1M |
|
16
Domino's
DPZ
$10.7B
| $1.16M | 1.53% |
6,304
+4,504
| +250% | +$807K |
|
17
Alibaba
BABA
$276B
| $1.06M | 1.4% |
9,855
+1,900
| +24% | +$193K |
|
|
OTIC
18
DELISTED
Otonomy, Inc.
OTIC
| $1.03M | 1.35% |
83,747
-34,726
| -29% | -$506K |
|
|
LJPC
19
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $989K | 1.3% |
+33,141
| New | +$846K |
|
20
Walt Disney
DIS
$170B
| $958K | 1.26% |
+8,449
| New | +$930K |
|
21
Rocket Pharmaceuticals
RCKT
$376M
| $956K | 1.26% |
119,441
+74,148
| +164% | +$499K |
|
22
Tyson Foods
TSN
$20.3B
| $913K | 1.2% |
+14,788
| New | +$932K |
|
|
ESPR
23
DELISTED
Esperion Therapeutics
ESPR
| $806K | 1.06% |
22,834
-6,359
| -22% | -$146K |
|
|
APC
24
DELISTED
Anadarko Petroleum
APC
| $744K | 0.98% |
+12,000
| New | +$798K |
|
25
AB InBev
BUD
$156B
| $718K | 0.95% |
+6,538
| New | +$703K |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q1 2017 Portfolio in Review
As of Q1 2017, FT Options held 408 positions worth $76M, down 13% from $87.1M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
FT Options deployed $112M of net new capital in Q1 2017, opening 159 new positions and adding to 53 existing holdings. Its largest new stake was GW Pharmaceuticals Plc American Depositary Shares: 25,829 shares worth $3.12M.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, down from 45% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $9.7M trimmed.
- FT Options's largest Q1 2017 buy was GW Pharmaceuticals Plc American Depositary Shares: 25,829 shares worth $3.12M.
- FT Options added most to Kellanova in Q1 2017, an estimated $2.19M increase.
- FT Options's biggest Q1 2017 reduction was Regeneron Pharmaceuticals, cutting an estimated $9.7M.
- FT Options fully exited JPMorgan Chase in Q1 2017, selling an estimated $3.58M.
- FT Options's ten largest holdings make up 38% of its $76M portfolio in Q1 2017.
- FT Options opened 159 new positions and closed 131 in Q1 2017.
- FT Options's portfolio value fell 13% quarter-over-quarter to $76M.
Based on FT Options's 13F filing for Q1 2017, filed 12 May 2017.